治疗前全身炎症标志物预测子宫内膜癌生存:日本妇科肿瘤组2043探索性数据分析
基于日本妇科肿瘤组2043数据,纳入712例子宫内膜癌患者,分析治疗前NLR、PLR和HALP评分与生存的关系。确定PFS相关最佳截断值分别为1.48、0.017、35.52,OS相关分别为1.88、0.026、19.87。HALP评分是无进展生存的预后因素(p=0.025),PLR和HALP评分是总生存的预后因素(均p=0.028)。
要点
- 治疗前HALP评分是子宫内膜癌无进展生存的预后因素(p=0.025)。
- 治疗前PLR和HALP评分是总生存的预后因素(均p=0.028)。
- NLR、PLR、HALP评分与BMI、年龄、临床分期等存在关联。
核心结论
- 治疗前全身炎症标志物与子宫内膜癌患者的生存结局相关,其中HALP评分是无进展生存和总生存的预后因素。
研究设计与样本
- 基于日本妇科肿瘤组2043数据的探索性分析,排除未接受化疗或失访患者,最终纳入712例患者(中位年龄55岁,范围28-74岁;BMI 21.1 kg/m2,范围15.2-38.6)。
- 分析治疗前中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和血红蛋白、白蛋白、淋巴细胞及血小板(HALP)评分与无进展生存(PFS)和总生存(OS)的关联。
- 确定NLR、PLR和HALP评分预测PFS和OS的最佳截断值,采用Kaplan-Meier法和log-rank检验计算并比较生存估计。
主要发现
- PFS相关最佳NLR、PLR和HALP评分截断值分别为1.48、0.017和35.52;OS相关分别为1.88、0.026和19.87。
- 在PFS相关最佳截断值下,NLR与BMI相关;PLR与年龄、BMI和临床分期相关;HALP评分与BMI、临床分期和淋巴结转移相关。
- 在OS相关最佳截断值下,NLR与BMI相关,PLR与BMI相关;HALP评分与年龄和BMI相关。
- HALP评分是PFS的预后因素(p=0.025),PLR和HALP评分是OS的预后因素(均p=0.028)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated whether pretreatment systemic inflammatory markers are associated with survival outcomes in patients with endometrial cancer (EC). METHODS: Data from the Japanese Gynecologic Oncology Group 2043 were analyzed. Patients who did not receive chemotherapy or were lost to follow-up were excluded. Associations of pretreatment systemic inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and hemoglobin, albumin, lymphocyte, and platelet (HALP) score, with progression-free survival (PFS) and overall survival (OS) were analyzed. The optimal NLR, PLR, and HALP score cutoff values for PFS and OS were determined. Survival estimates were calculated and compared using the Kaplan-Meier method and log-rank test. RESULTS: We included 712 patients (median age: 55 [range, 28-74] years; body mass index [BMI]: 21.1 [15.2-38.6] kg/m2). For PFS, optimal NLR, PLR, and HALP score cutoff values were 1.48, 0.017, and 35.52, respectively, and for OS, the values were 1.88, 0.026, and 19.87, respectively. At optimal PFS-related cutoff values, NLR was associated with BMI; PLR with age, BMI, and clinical stage; and HALP score with BMI, clinical stage, and lymph node metastasis. At optimal OS-related cutoff values, NLR was associated with BMI, PLR, and BMI; the HALP score was associated with age and BMI. The HALP score was a prognostic factor for PFS (p = 0.025), while PLR and HALP scores were prognostic factors for OS (both p = 0.028). CONCLUSIONS: Pretreatment systemic inflammatory markers are associated with survival outcomes in patients with EC, with the HALP score being a prognostic factor for PFS and OS.
引用
- Nishio S, Murotani K, Yamagami W, et al. Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis. Gynecol Oncol. 2023. PMID: 38113633. doi:10.1016/j.ygyno.2023.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。